Filters

 

Resource Type
Celebrating positive male role models: International Men's Day 2024

IQ Consortium’s In Vitro Secondary Pharmacology Profiling Working Group article ‘The state of the art in secondary pharmacology and its impact on the safety of new medicines’ recognised as the ‘Most Impactful Safety Pharmacology Publication of the Year’.

Read More
Secondary pharmacology publication recognised as ‘Most Impactful Publication of the Year’ by the Safety Pharmacology Society

IQ Consortium’s In Vitro Secondary Pharmacology Profiling Working Group article ‘The state of the art in secondary pharmacology and its impact on the safety of new medicines’ recognised as the ‘Most Impactful Safety Pharmacology Publication of the Year’.

Read More
Publication in support of refining the hERG testing strategy for silencing RNA (siRNA) receives ‘2024 Technology Innovation Publication Award’ from the Safety Pharmacology Society

'Time Is a Critical Factor When Evaluating Oligonucleotide Therapeutics in Human Ether-a-Go-Go-Related Gene Assays’ (Nucleic Acid Therapeutics) receives ‘2024 Technology Innovation Publication Award’.

Read More
High-quality, cost-effective and rapid-turnaround, GLP testing against hERG

Metrion Biosciences provides GLP hERG testing services which crucial for drug discovery and the Investigational New Drug (IND) process. Our focus is on delivering reliable, regulatory-compliant data quickly and cost-effectively.

Read More
Importance of GLP hERG testing: Ensure data regarding a drug’s potential to cause cardiac arrhythmias is reliable, giving confidence that it can be used in regulatory decision making

The hERG gene encodes a potassium ion channel that is essential for repolarizing the cardiac action potential. Inhibition of this channel can prolong the QT interval on an electrocardiogram (ECG), leading to a condition called Torsades de Pointes (TdP), a potentially fatal arrhythmia.

Read More
The path to my industrial placement at Metrion Biosciences: Beth Sharp

I am currently studying Biomedical Sciences at the University of Manchester. Through my previous years of education, I enjoyed studying biology and engaging in practical experiments, particularly those with clinical relevance, which ultimately guided my degree selection.

Read More
Metrion Biosciences appoints Dr Chris Mathes as Chief Commercial Officer
Read More
Supporting an integrated QTc risk assessment using the hERG margin distributions for three positive control agents derived from multiple laboratories and on multiple occasions

The recent ICH E14/S7B Q&As have provided more clarity on the methodologies that should be employed when conducting a GLP hERG to support and IND filing for a novel clinical compound.

Read More
Industrial placement review: Molly Rowlett

My 12 month industrial placement at Metrion Biosciences was a truly remarkable experience that has helped me grow both personally and professionally. Choosing to complete a placement year was a big decision for me which was made 100% worth it!

Read More
Development and validation of a dual modality TREK-1 screening assay on the automated patch clamp Qube 384 platform

Two-pore domain K+ (K2P) channels are a family of four-pass transmembrane K+ channels that dimerise, as homomers or heteromers, to form a functional K+ channel complex capable of regulating membrane potential through a background K+ conductance.

Read More
1 2 3 4
Metrion Biosciences

Let’s work together

If you have any questions or would like to discuss your specific assay requirements, we will put you directly in touch with a member of our scientific team. Contact us today to discover more.
Contact us for a quote or discussion
Metrion Biosciences is a contract research organisation (CRO) specialising in high-quality preclinical drug discovery services.
magnifier
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram